OmniAb, Inc. (OABI) vs Prime Medicine, Inc. (PRME)
A side-by-side comparison of OmniAb, Inc. and Prime Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OABI
OmniAb, Inc.
$4.25HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
PRME
Prime Medicine, Inc.
$3.59HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
Total return — OABI vs PRME
growth of $100 · dividends reinvested · last 4yOABI -45.3% (-14.0%/yr)PRME -79.1% (-32.4%/yr)OABI compounded faster over this window
OABI PRME
OABI vs PRME: by the numbers
- •PRME is the larger company ($648M vs $616M market cap).
- •Both run net losses; OABI's is the smaller (-115.18% vs -4613.11% net margin).
- •Both shrank revenue over the past five years; PRME's decline was smaller (-2.32% vs -4.31% CAGR).
Metrics side by side
Valuation
| Metric | OABI | PRME |
|---|---|---|
| P/S ratio | 16.04 | 158.98 |
| P/B ratio | 2.37 | 16.27 |
Profitability
| Metric | OABI | PRME |
|---|---|---|
| Gross margin | -18.17% | -58.05% |
| Operating margin | -383.15% | -4498.06% |
| Net margin | -115.18% | -4613.11% |
| ROE | -17.01% | -471.98% |
| ROIC | -17.48% | -90.42% |
Growth (annualized)
| Metric | OABI | PRME |
|---|---|---|
| Revenue CAGR (5Y) | -4.31% | -2.32% |
| Total return CAGR (5Y) | -13.17% | N/A |
Frequently asked
- Which has grown faster, OABI or PRME?
- Neither grew: over the past five years both shrank revenue, with PRME's decline the smaller — OABI at a -4.31% CAGR versus PRME at -2.32%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.